Results of multiple studies have shown that a proportion of men with advanced prostate cancer carry germline DNA damage repair mutations. This article summarizes recommendations for germline testing in prostate cancer and describes care models for providing counseling and testing.
ME-344 and bevacizumab can now have an additional 20 patients enrolled on the phase 1b trial for relapsed metastatic colorectal cancer.
The FDA approval of the single-agent, oral pan-RAF inhibitor tovorafenib is based on efficacy results from the phase 2 FIREFLY-1 trial.
DCISionRT is a risk-assessment test for patients designed to predict RT benefit and develop their recurrence risk after surgery alone or with radiation.
Data from 2 NETTER trials support lutetium Lu 177 dotatate’s approval in somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors.
Nogapendekin alfa-inbakicept is now approved for the treatment of patients with BCG-unresponsive non-muscle invasive bladder carcinoma.
The latest KEYNOTE-756 data highlight the surgical outcomes of patients with high-risk early-stage estrogen receptor–positive breast cancer.
In clinically node-positive breast cancer, clipping of lymph nodes may induce higher rates of sentinel lymph node surgery after neoadjuvant chemotherapy.
The FDA has approved alectinib for the adjuvant treatment of patients with ALK-positive non-small cell lung cancer with tumors that are least 4 cm or…
The expert panel provides closing remarks on exciting developments in the evolving treatment landscape in multiple myeloma.
Sumanta Kumar Pal, MD, FASCO, joins Rohit Gosain, MD, and Rahul Gosain, MD, to discuss risk stratification and treatment practices for patients with localized kidney…
